RxDoctor Payments Data

Julia Barry, DO

Cardiovascular Disease · Tallahassee, FLNPI 1356760763

Payments from drug & device makers

$960in general payments, 2019–2025

Across 53 payments — averaging $18.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$240
  • Medtronic$162
  • Merck$158
  • Bayer$73
  • Novartis$64
  • Boston Scientific$52
  • plus $211 from 8 others

What the payments were for

  • Food & beverage$960100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$960 in reported general payments places this provider in the 25th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$139,485
Medicare patients
416
Services billed
1,332

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban366$307,956
EntrestoSacubitril/Valsartan129$107,634
Repatha SureclickEvolocumab109$87,213
FarxigaDapagliflozin Propanediol86$69,546
JardianceEmpagliflozin74$58,266
BrilintaTicagrelor36$19,627
XareltoRivaroxaban26$17,863
Ranolazine ErRanolazine197$15,691
Metoprolol Succinate488$7,364
Icosapent Ethyl29$7,314
Atorvastatin Calcium600$7,130
Carvedilol310$2,887
Dabigatran EtexilateDabigatran Etexilate Mesylate16$2,667
Rosuvastatin Calcium155$2,399
Ezetimibe176$2,341

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$42$307,956366 claims
NovartisEntresto$64$107,634129 claims
AstraZenecaFarxiga, Brilinta$49$89,173122 claims
Boehringer IngelheimJardiance$20$58,26674 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →